09:53:58 EDT Fri 12 Jul 2024
Enter Symbol
or Name
USA
CA



Login ID:
Password:
Save

Q:NRBO - NEUROBO PHARMACEUTICALS INC - Website unknown - click to update
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
NRBO - Q0.14.66·4.810.14.67+0.010.21.04144.68  4.68  4.676.7499  2.9009:35:01Jul 1115 min RT 2¢

Recent Trades - Last 10 of 14
Time ETExPriceChangeVolume
09:35:01Q4.66 1
09:34:40Q4.67120.011254
09:34:40Q4.670.01100
09:31:15Q4.67460.0146100
09:30:06Q4.740.081
09:30:03Q4.740.081
09:30:03Q4.740.081
09:30:02Q4.740.081
09:30:02Q4.740.081
09:30:01Q4.680.02380

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2024-07-11 08:01U:NRBONews ReleaseNeuroBo Pharmaceuticals to Present at the Emerging Growth Conference in July
2024-06-26 09:06U:NRBONews ReleaseNeuroBo Pharmaceuticals Doses First Patient in the MAD Part 2 of Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity
2024-06-25 17:07U:NRBONews ReleaseNeuroBo Pharmaceuticals Announces the Closing of up to $70 Million Concurrent Private Placement and Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
2024-06-24 08:01U:NRBONews ReleaseNeuroBo Pharmaceuticals Announces up to $70 Million Concurrent Private Placement and Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
2024-06-22 08:01U:NRBONews ReleaseNeuroBo Pharmaceuticals' DA-1726 Demonstrated Superiority in Weight Loss, Retention of Lean Body Mass, and Lipid-Lowering Effects Compared to Survodutide, in Pre-Clinical Models
2024-05-22 08:01U:NRBONews ReleaseNeuroBo Pharmaceuticals' DA-1241 in Combination with Semaglutide Improves Liver Fibrosis and Demonstrates Additive Hepatoprotective Effects in Pre-Clinical MASH Models Compared to Either Treatment, Alone
2024-05-09 08:01U:NRBONews ReleaseNeuroBo Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update
2024-04-30 08:01U:NRBONews ReleaseNeuroBo to Present Latest Pre-Clinical Data on Cardiometabolic Assets, DA-1241 and DA-1726, Targeting MASH and Obesity, at Scientific Conferences in June
2024-04-17 08:05U:NRBONews ReleaseNeuroBo Pharmaceuticals Doses First Patient in Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity
2024-04-01 08:01U:NRBONews ReleaseNeuroBo Pharmaceuticals Completes Enrollment of Part 1 of Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASH
2024-03-28 08:01U:NRBONews ReleaseNeuroBo Pharmaceuticals Reports Year End 2023 Financial Results and Provides Corporate Update
2024-03-13 08:01U:NRBONews ReleaseNeuroBo Pharmaceuticals Receives Safety Review Committee Approval to Continue With Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASH
2024-03-04 08:01U:NRBONews ReleaseNeuroBo Pharmaceuticals Appoints Seasoned Life Science Executive Marshall Woodworth as Chief Financial Officer
2024-02-29 08:01U:NRBONews ReleaseNeuroBo Pharmaceuticals Receives First Site IRB Approval for Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity
2024-02-12 08:01U:NRBONews ReleaseNeuroBo Pharmaceuticals to Participate in the BIO CEO & Investor Conference
2024-02-01 08:01U:NRBONews ReleaseNeuroBo Pharmaceuticals Announces FDA Clearance of IND for a Phase 1 Clinical Trial of DA-1726 for the Treatment of Obesity
2024-01-18 08:01U:NRBONews ReleaseNeuroBo Pharmaceuticals Reports Positive Pre-Clinical Safety Data of DA-1241 in Combination with Sitagliptin and Opens Enrollment for Part 2 of Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASH
2024-01-09 08:30U:NRBONews ReleaseNeuroBo Pharmaceuticals Regains Compliance with Nasdaq Minimum Price Requirement
2024-01-02 08:01U:NRBONews ReleaseNeuroBo to Participate in Industry and Investor Conferences in January
2023-12-28 08:45U:NRBONews ReleaseNeuroBo Pharmaceuticals Submits IND Application to the FDA for a Phase 1 Clinical Trial of DA-1726 for the Treatment of Obesity